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Key Clinical Message
In an intestinal transplant patient under triple immunosuppression therapy
with tacrolimus levels >10 ng/L, a 2-day oral immunoglobulin therapy given as
treatment for chronic norovirus infection was temporally closely associated with
the development of severe steroid-resistant acute graft rejection, thus suggesting
that oral immunoglobulin might be able to promote a rejection response.
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Introduction
Immunoglobulin was originally used as replacement ther-
apy in hypogammaglobulinemia patients, but has there-
after been used as off-label treatment for a wide variety of
difficult-to-treat autoimmune and inflammatory condi-
tions including antibody-mediated graft rejection after
solid-organ transplantation [1, 2].
Oral administration of immunoglobulin has been
shown to be effective in infectious gastroenteritis [3],
including chronic norovirus infection in intestinal trans-
plant patients [4].
Immunoglobulin preparations comprise pooled
immunoglobulin G (IgG) antibodies from sera of thou-
sands of blood donors and exert immunomodulatory
effects that are complex and incompletely understood [1].
Immunoglobulin can exert both pro- and anti-inflamma-
tory activities. Although the anti-inflammatory effects are
usually desired in therapy, the consequences of pro-
inflammatory effects remain poorly studied [1]. Very little
is known about the local intestinal effects of oral
immunoglobulin.
We report a case where the use of oral immunoglobu-
lin for chronic norovirus infection was temporally closely
associated with the development of severe steroid-resistant
acute graft rejection in a previously immunologically
stable intestinal transplant patient.
Case Report
A 34-year-old Caucasian male had undergone intestinal
transplantation originally more than 3 years ago because
of chronic intestinal pseudo-obstruction due to familial
visceral myopathy [5]. The first intestinal transplant was
lost due to volvulus 2 months post-transplant. Retrans-
plantation was performed 18 months ago. Viremic cyto-
megalovirus (CMV) gastroenteritis was diagnosed 1 year
post-transplant. Treatment with intravenous ganciclovir
and later oral valganciclovir was successful, and CMV PCR
remained negative in blood and intestinal biopsies during
follow-up. The patient also suffered another volvulus of
the colon, which was successfully corrected operatively.
Mild grade 1 acute rejection in the colon occurred
2 months later; the small intestine was normal. The
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rejection resolved quickly with intravenous steroids; fol-
low-up biopsies at 1 week were normal. After the rejection
episode, there were nine follow-up endoscopies showing
only mild segmental erythema and distorted mucosal vas-
cular pattern on a confined area in the colon; we specu-
lated the previous volvulus as a cause for these mild
findings. In biopsy specimens, there were no signs of rejec-
tion or inflammation, and viral samples were negative.
Norovirus gastroenteritis was diagnosed 2 months after
the rejection. The patient was admitted to the hospital
due to dehydration, abdominal pain, and fever. Prior to
this, the patient’s family members had suffered symptoms
of gastroenteritis, presumably of viral origin. In our
patient, gastroenteritis symptoms with watery diarrhea
persisted, and the patient needed repeated episodes of
hospitalization due to dehydration. Norovirus PCR from
the stools remained repeatedly positive, and the norovirus
infection was considered a cause for the chronic diarrhea.
Endoscopy findings were unchanged. Nearly 3 months
after the initial norovirus infection diagnosis, treatment
with oral immunoglobulin was started. An intravenous
immunoglobulin solution (Privigen) was given orally at
a dose of 1250 mg (25 mg/kg body weight) four times
daily for 2 days (altogether eight doses). The
immunoglobulin solution did not bypass the gastric
barrier. Tacrolimus trough levels during the preceding
4 months had been stable above 10 ng/L (range 11.5–
18.3 ng/L), and the patient had received triple immuno-
suppression therapy with MPA 360 mg twice daily and
methylprednisolone 6 mg daily.
Four days after the end of the immunoglobulin treat-
ment, the patient was again admitted to hospital due to
fever, increased diarrhea, and abdominal pain. Endo-
scopy via colostomy was performed, and severe biopsy-
proven rejection grade 2–3 was diagnosed in the small-
bowel and colon (Fig. 1 and Fig. 2). CMV and Epstein–
Barr virus samples were negative. Tacrolimus trough
level was 12.4 ng/L. Initial therapy was by high-dose
intravenous methylprednisolone. However, signs of rejec-
tion persisted on repeat endoscopy, and finally, a 10-day
course of intravenous antithymocyte globulin was
started, whereby the acute rejection resolved both symp-
tomatically and in graft biopsies (Fig. 1). Donor-specific
antibodies were negative. Follow-up endoscopies showed
persisting signs of colitis and distal ileitis, but these
finally resolved at 3 months after starting immunoglobu-
lin therapy, and the patient has remained rejection-free
now 10 months later.
The norovirus infection persisted, and the patient was
started on nitazoxanide 500 mg twice daily, but without
(A) (B)
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Figure 1. Endoscopic view of the small bowel transplant (A) before the acute rejection, (B, C) at diagnosis of acute rejection, and (D) after
steroid- and antithymocyte globulin therapy.
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any clear clinical or virologic response. Bacterial, other
viral, and parasitic samples were negative (Fig. 2).
Discussion
The main message with our case is that oral
immunoglobulin used to treat persistent norovirus infec-
tion could have triggered severe intestinal allograft rejec-
tion. Treatment of the chronic norovirus infection was
indicated in our patient because the amounts of colosto-
mal secretions remained high during the norovirus infec-
tion, leading to repeated dehydration episodes with
acidosis and serum creatinine increases.
Possible causality between the immunoglobulin use and
subsequent rejection cannot be confirmed. However, there
was a very close temporal relationship between
immunoglobulin use and the severe rejection, and, prior
to this, nine endoscopies had been normal, immunosup-
pression was strong with triple therapy, and tacrolimus
trough levels had been >10 ng/L. The norovirus infection
was chronic and has not been reported to induce rejec-
tion. Based on this, we consider it likely that oral
immunoglobulin treatment induced allograft rejection.
The immunoglobulin preparation (Privigen) used in
our patient comprises 98% IgG and is developed from
human plasma comprising pooled fraction of serum
immunoglobulin from at least 1000 donors. Little is
known about side-effects from immunoglobulin when
administered orally.
Orally administered immunoglobulin has been shown to
survive gastric exposure and proteolytic digestion, with the
amount of intact IgG recovered in stool reportedly up to
50% [6]. The effects of oral immunoglobulin are, in gen-




Figure 2. Histologic pictures of endoscopic biopsy samples from the small-bowel graft. Before the acute rejection normal histology was
demonstrated (A, magnification 9100; B, magnification 9400). At diagnosis of acute rejection moderate to severe inflammation with abundant
apoptosis was seen (C, magnification 9100; D, magnification 9400). After steroid- and antithymocyte globulin therapy acute rejection was
ameliorated and nearly normal histology was again detected (E, magnification 9100; F, magnification 9400).
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for a therapeutic benefit in, for instance, inflammatory
bowel disease [3]. However, published experience with the
use of oral immunoglobulin in intestinal transplant
patients is very scarce. Small case series have indicated that
oral immunoglobulin is effective in the treatment of
chronic norovirus infection in intestinal transplant patients
and other solid-organ transplant patients [4, 7]. Norovirus
replicates within the gut lumen, and it has been speculated
that oral immunoglobulin can block viral adherence to
intestinal epithelium and inhibit viral replication by form-
ing complexes with the virus [3]. Currently, there exist no
effective antiviral drugs specifically for norovirus. However,
nitazoxanide, an antiprotozoal drug, has shown effect in
the treatment of chronic norovirus in immunosuppressed
patients [8]. In our case, however, we observed no clear
response to nitazoxanide treatment.
The possible causal link between oral immunoglobulin
use and allograft rejection, observed in our patient, is
unclear. There are unique immune challenges with the
intestinal allograft as the intestine harbors a high load of
lymphoid cell populations, and the gut lumen is colonized
by a complex microbiota. Gut microbial composition and
function, the interplay between microbiota and intestinal
cells, and inflammatory responses all likely affect allore-
sponses in intestinal transplant patients [3, 9]. Specific
microbial communities have been shown to promote effec-
tor and regulatory T-cell responses [9], and changes in gut
microbiota are associated with intestinal transplant rejection
[10]. It can be speculated that oral immunoglobulin could
alter gut microbiota, interfere with local inflammatory pro-
cesses, and thereby affect alloresponses [3, 9]. However,
direct triggering of allograft rejection by oral immunoglobu-
lin use has, to our knowledge, not been reported. Possible
residual injury to the gut from previous volvulus and/or
chronic norovirus infection might also have contributed to
these responses and to graft susceptibility.
In conclusion, in our intestinal transplant patient, a
strong temporal relationship between the use of oral
immunoglobulin for chronic norovirus infection and subse-
quent severe steroid-resistant acute rejection raises concern
for the possible potential of oral immunoglobulin in stimu-
lating allograft immunologic responses. However, causality
remains uncertain, and more clinical experience is needed.
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